Srikrishna Ramakarthikeyan

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Hexaware revenue grew 18% but profit fell 13%. Why is Vivek Jetley replacing its 12-year CEO?

Hexaware Technologies has appointed EXL veteran Vivek Jetley as CEO-designate to succeed Srikrishna Ramakarthikeyan after 12 years, putting an AI and analytics specialist in charge as revenue expands but profitability faces pressure.

byPallavi Madhiraju

September 3, 2026

Is Hexaware Technologies’ (NSE: HEXT) patent dispute relief enough to change the stock sentiment story?

Read how Hexaware Technologies’ U.S. patent claims dismissal may ease #HEXT litigation risk as the stock trades far below its high.

bySrinath

June 12, 2026

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Hexaware revenue grew 18% but profit fell 13%. Why is Vivek Jetley replacing its 12-year CEO?

Is Hexaware Technologies’ (NSE: HEXT) patent dispute relief enough to change the stock sentiment story?

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?